(Q52903912)

9 May 2018

title

Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma. (English)

1 reference

9 May 2018

0 references

Maja A Hofmann

1

1 reference

9 May 2018

Felix Kiecker

2

1 reference

9 May 2018

Ingeborg Küchler

3

1 reference

9 May 2018

Christian Kors

4

1 reference

9 May 2018

Uwe Trefzer

5

1 reference

9 May 2018

publication date

9 May 2010

1 reference

9 May 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

9 May 2018

volume

137

1 reference

9 May 2018

issue

3

1 reference

9 May 2018

page(s)

455-462

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s00432-010-0900-1

exact match

0 references

cites work

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Health management program: factors influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Interferons, interferon-like cytokines, and their receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Genetic factors predicting response to interferon treatment for viral hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

TNF downmodulates the function of human CD4+CD25hi T-regulatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Expression of biomarkers of interferon type I in patients suffering from chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-010-0900-1

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

21 January 2018

1 reference

12 December 2020

Concentration of b2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-a therapy

1 reference

12 December 2020

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

12 December 2020

Interleukin 10 production by human melanoma

1 reference

12 December 2020

TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice

1 reference

12 December 2020

Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma

1 reference

12 December 2020

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

12 December 2020

A polymorphic dinucleotide repeat in the human IL-10 promoter

1 reference

12 December 2020

Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm

1 reference

12 December 2020

Soluble interleukin-2 receptor in stage I–III melanoma

1 reference

12 December 2020

Interleukin-10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients

1 reference

12 December 2020

Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis.

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

12 December 2020

10.1007/S00432-010-0900-1

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018